Gate Insights and Crypto Market Analysis

Gate Insights features in-depth crypto analysis, market trends, and long-form articles to help you understand key movements across the crypto industry.

Jim Cramer's Trust Buys 100 Intel Shares at $97.97 as AI Trade Recovers

Jim Cramer's Charitable Trust is buying 100 shares of Intel at roughly $97.97 shortly after the opening bell. Following the trade, the Trust will own 1,300 shares of INTC, increasing its portfolio weight to about 3.20% from 3%. The purchase aims to build out the position and lower the average cost b
INTC-5.22%
AMD-3.88%
GateMacroTradfiHub·08-05 12:44
Jim Cramer's Trust Buys 100 Intel Shares at $97.97 as AI Trade Recovers

Orion Launches Fractional Share Trading for RIAs Using Schwab Custody

Orion introduced fractional share trading for financial advisors who custody client assets with Schwab Advisor Services, enabling portfolios to be invested to precise dollar targets instead of being constrained by whole-share purchases. The capability addresses a core challenge for registered invest
NVDA-2.86%
AMZN-2.21%
GateMacroTradfiHub·08-05 12:42
Orion Launches Fractional Share Trading for RIAs Using Schwab Custody

UK Services PMI Expands to 52.1 in July, First Growth Since April

S&P Global announced on August 5 that the UK's July services Purchasing Managers' Index (PMI) final reading reached 52.1, marking the sector's first expansion since April. The figure exceeded both the preliminary reading of 51.8 and the prior month's 48.8. The growth was driven by increased
GateMacroTradfiHub·08-05 10:59
UK Services PMI Expands to 52.1 in July, First Growth Since April

Palantir Stocks Rally 30% as CEO Karp Gains Billions in Single Session

Palantir CEO Alex Karp's net worth increased by billions on Tuesday as Palantir stocks extended their rally to nearly 30% in a single trading session, according to Forbes real-time billionaire rankings. The surge followed the company's Monday announcement of second-quarter revenue of $1.94 billion,
PLTR2.39%
GateMacroTradfiHub·08-05 10:58
Palantir Stocks Rally 30% as CEO Karp Gains Billions in Single Session

Eli Lilly Q2 Earnings Beat Estimates as Zepbound, Mounjaro Sales Surge

Eli Lilly reported second-quarter earnings and revenue that surpassed estimates on Wednesday and raised its full-year sales outlook, driven by surging demand for weight loss drug Zepbound and diabetes treatment Mounjaro. The pharmaceutical giant posted adjusted earnings of $8.38 per share on revenue
GateMacroTradfiHub·08-05 10:54
Eli Lilly Q2 Earnings Beat Estimates as Zepbound, Mounjaro Sales Surge